Browsing: Basic > Drug Development
This editorial presents some of the latest evidence to support the antivirulence approach, highlighting at the same time some of the issues that need to be considered when evaluating antivirulence drugs.
In this podcast Dr Elizabeth Whittaker, Dr James Seddon, Dr Pete Dodd and Professor Beate Kampmann discuss their work in pediatric tuberculosis focusing on the areas of immunology, modelling and drug resistance.
Take a look at our new infographic, developed for World Tuberculosis Day, which explores the facts about current TB burden, the issues around drug resistance, and research and development moving forwards.
In this original research article, the authors determine the structural contributions of a compound set containing inhibitors of bacterial enzyme FabI.
Mark Blaskovich, Principal Investigator and Program Coordinator for the Community for Open Antimicrobial Drug Discovery (CO-ADD) discusses his work towards uncovering compounds with antibiotic potential and shares his thoughts on the best strategies to tackle antibiotic resistance moving forwards.
Researchers from Durham University have developed a new, simplified production process for a drug vital to treating cryptococcal meningitis; they hope this will reduce the drug’s cost and increase its availability in developing countries.